I agree BlackDoggie, and if I may add (since I am one of the people focused on CTC), I think that the mTNBC trial will be predominantly focused on CTC as most of these patients will be enrolled earlier in the progression of cancer and may not show as significant of reductions in tumor size due to the fact that they are not as large or metastatic.

The emergency IND/Basket trial patients, as I understand it, will be much further along, typically with multiple progressive tumors that may show tumor shrinkage much earlier (such as with Nadars MIL)

I think we need to show both low CTC in early patients, and tumor shrinkage in advanced patients as it will increase our chances of a BTD